Moderna generated 678000000 in revenue in Q4 2025, driven primarily by COVID vaccine sales, and reported a net loss of 826000000 as the company continued investing in R&D while reducing operating expenses year-over-year.

Moderna posted a net loss of $200 million and revenue of $1.0 billion in Q3 2025, reflecting reduced COVID vaccine sales, though the company improved its cost structure and narrowed its full-year outlook.

Moderna's Q2 2025 results reflected a continued downturn in COVID-19 vaccine sales, leading to a 41% drop in revenue. Despite the decline, the company reduced its net loss compared to last year and achieved cost savings in R&D and SG&A. Multiple new FDA approvals and pipeline progress are expected to drive future performance.

Moderna saw a decline in revenue and continued net losses in Q1 2025, attributed to lower vaccination rates and the seasonal nature of its respiratory business. Despite financial challenges, the company is progressing on a robust pipeline, including oncology and rare disease candidates.

Moderna reported a sharp year-over-year revenue decline in Q4 2024, primarily driven by reduced demand for its COVID-19 vaccine. The company posted a substantial net loss and negative operating income, reflecting restructuring costs and lower sales volumes. Despite these challenges, Moderna continued advancing its late-stage pipeline and cost-cutting initiatives.

Moderna's Q3 2024 financial results showed revenues of $1.9 billion, driven by Spikevax® sales. The company achieved a GAAP net income of $13 million and EPS of $0.03. Cost efficiency was a key focus, contributing to improved financial performance.

Moderna reported second quarter revenues of $241 million, a GAAP net loss of $1.3 billion, and a GAAP EPS of $(3.33). The company updated its 2024 financial framework and revised expectations for product sales to $3.0 to $3.5 billion. Moderna received U.S. FDA approval for its RSV vaccine, mRESVIA, and began shipping in July. Positive Phase 3 data was announced for both a combination vaccine against influenza and COVID-19 and a next-generation COVID-19 vaccine.

Moderna reported first quarter revenues of $167 million, a GAAP net loss of $1.2 billion, and a GAAP diluted EPS of $(3.07). The company is preparing for the launches of its RSV vaccine and Spikevax® 2024-2025 formula and reaffirms its 2024 expected product sales of approximately $4 billion.

Moderna's Q4 2023 revenue was $2.8 billion, with a net income of $217 million and diluted EPS of $0.55. The company's full-year revenue was $6.8 billion, with a net loss of $4.7 billion and diluted EPS of $(12.33). The company reaffirms its 2024 product sales guidance of $4 billion.

Moderna reported third quarter 2023 revenues of $1.8 billion, primarily from Spikevax sales. The company experienced a net loss of $3.6 billion, mainly due to non-cash charges related to manufacturing resizing and tax valuation allowances. Moderna is preparing for multiple product launches through 2025 and expects to return to sales growth in 2025, aiming to break even in 2026.

Moderna reported second quarter 2023 revenues of $0.3 billion, a net loss of $1.4 billion, and a loss per share of $3.62. The company is on track to deliver 2023 sales between $6 billion to $8 billion, dependent on COVID vaccination rates in the U.S.

Moderna reported first quarter 2023 revenues of $1.9 billion and GAAP net income of $79 million, with a diluted EPS of $0.19. The company is in negotiations for new orders for the fall of 2023 and preparing for potential 2024 commercial launches of its investigational RSV vaccine.

Moderna's Q4 2022 revenue was $5.1 billion, a decrease from $7.2 billion in Q4 2021. Net income also decreased to $1.5 billion from $4.9 billion in the same period. The company is focusing on expanding its vaccine pipeline and expects approximately $5 billion in COVID-19 sales for 2023.

Moderna's Q2 2022 earnings showcased a robust performance with $4.7 billion in revenue and a GAAP net income of $2.2 billion. The company is reiterating advance purchase agreements for approximately $21 billion in expected deliveries for 2022 and announcing a new $3 billion share repurchase plan. Moderna has four infectious disease vaccines in Phase 3 and expects data from proof-of-concept studies in rare diseases and immuno-oncology later this year.

Moderna reported a strong first quarter with revenues of $6.1 billion, driven by increased product sales of its COVID-19 vaccine. The company's GAAP net income was $3.7 billion, with a diluted EPS of $8.58. Moderna reiterated its 2022 signed advance purchase agreements of approximately $21 billion.

Moderna reported Q4 2021 revenues of $7.2 billion, a significant increase compared to $571 million in the same period of 2020. GAAP net income for the quarter was $4.9 billion, with a diluted EPS of $11.29. The company's full year revenue reached $18.5 billion, with a net income of $12.2 billion and diluted EPS of $28.29.

Moderna reported a significant increase in revenue, driven by the commercial sales of its COVID-19 vaccine. The company's net income and EPS also saw substantial growth compared to the same period last year. Moderna is also advancing its pipeline with multiple programs in development, including vaccines for CMV, flu, and RSV.

Moderna reported Q2 2021 total revenue of $4.4 billion, a significant increase from $67 million in the same period of 2020. Net income for the quarter was $2.8 billion, compared to a net loss of $117 million in Q2 2020. The company's COVID-19 vaccine demonstrated durable efficacy of 93% through six months, and booster candidates showed robust antibody responses to variants of concern.

Moderna reported its first profitable quarter in the company's history, with total revenue reaching $1.9 billion, driven by sales of its COVID-19 vaccine. The company delivered on its supply commitments and increased its 2021 supply forecast to between 800 million and 1 billion doses.

Moderna reported a significant increase in revenue for Q4 2020, driven by grant revenue and product sales of its COVID-19 vaccine. The company is expanding its manufacturing capabilities and advancing its mRNA development programs.

Moderna's Q3 2020 saw revenue of $157.9 million, primarily driven by increases in grant revenue related to the BARDA agreement for the mRNA-1273 vaccine candidate. The company's net loss was $233.6 million. Moderna received $1.1 billion in customer deposits for the supply of mRNA-1273, recorded as deferred revenue.